Ireland-based Endo International plc (OTC:ENDPQ), a specialty pharmaceutical company, announced on Monday that one of its operating companies, Par Pharmaceutical, Inc, has commenced shipping of the authorised generic (AG) version of Merck's Noxafil (posaconazole) 200mg/5mL oral suspension in the United States.

Endo Ventures Limited, a subsidiary of Endo, has signed an exclusive US supply and distribution agreement with a subsidiary of Merck & Co., Inc. of Rahway, New Jersey. The distribution agreement is intended to enable Par Pharmaceutical to introduce and distribute an authorised generic version of the product. The contract also included the authorised generic version of Noxafil delayed-release tablets, 100 mg, which was launched in 2019.

The product is a registered trademark of Merck Sharp & Dohme LLC.